Patent ID: 8802718

Claim:
A method of reducing occurrence of a cardiovascular event in a hypercholesterolemia patient comprising, identifying a patient having triglycerides (TG) of at least 150 mg/DL, and HDL-C of less than 40 mg/dL in a blood sample taken from the patient as the only risk factor of a cardiovascular event, wherein the patient has not previously had a cardiovascular event, and administering ethyl icosapentate in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor; wherein the rate of suppression of the cardiovascular event occurrence in the said administered patient group is equal to or more than 48% compared to the control patient group after 2 years or more from the start of said administration; and wherein the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor is selected from the group consisting of pravastatin, lovastatin, simvastatin, fluvastatin, atorvastatin, pitavastatin, rosuvastatin, and salts thereof.